Vikasdeep Gupta¹ and Vandana Sharma²*

¹Department of Ophthalmology, All India Institute of Medical Sciences (AIIMS), Bathinda, India
²Department of Ophthalmology, Adesh Institute of Medical Sciences and Research (AIMSR), Bathinda, India

*Corresponding Author: Vandana Sharma, Department of Ophthalmology, Adesh Institute of Medical Sciences and Research (AIMSR), Bathinda, India.

Received: March 14, 2022; Published: March 28, 2022

Abstract

COVID 19 pandemic has overburdened the healthcare infrastructure in India in the last few months. As the second wave recedes, mucormycosis emerged as a new nemesis which is life and vision threatening to the already immunocompromised post COVID patients. This review article is written with the intent to identify a definitive approach towards early identification of the disease and to formulate guidelines for prompt management.

Keywords: Mucormycosis; COVID-19; Infrastructure

References

1. Sharma S., et al. “Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum”. Journal of Laryngology and Otology 5 (2021): 442-447.
2. Kontoyiannis DP., et al. “Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases”. Journal of Infectious Disease8 (2005): 1350-1360.
3. V Saegeman., et al. “Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital”. Medical Mycology2 (2010): 245-254.
4. Chayakulkeeree M., et al. “Zygomycosis: the re-emerging fungal infection”. European Journal of Clinical Microbiology and Infection Disease 4 (2006): 215-229.
5. Kauffman CA. “Zygomycosis: reemergence of an old pathogen”. Clinical Infectious Diseases4 (2004): 588-590.
6. Safdar A., et al. “Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis”. Bone Marrow Transplantation5 (2004): 467-468.
7. Marr KA., et al. “Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients”. Clinical Infectious Diseases 7 (2002): 909-917.
8. Roden MM., et al. “Epidemiology and outcome of zygomycosis: a review of 929 reported cases”. Clinical Infectious Diseases 5 (2005): 634-653.
9. Chakrabarti A., et al. “Ten years' experience in zygomycosis at a tertiary care centre in India”. Journal of Infection4 (2001): 261-266.
10. White L., et al. “A national strategy to diagnose coronavirus disease 2019 - associated invasive fungal disease in the intensive care unit”. Clinical Infectious Diseases (2020): ciaa1298.
11. Gangneux JP., et al. “Invasive fungal diseases during COVID-19: we should be prepared”. Journal of Medical Mycology 30 (2020):
12. Arnaiz-Garcý´a ME., et al. “Cutaneous mucormycosis: report of five cases and review of the literature”. Journal of Plastic, Reconstructive and Aesthetic Surgery 62 (2009): 434e441.
13. Chamilos G., et al. “Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis”. Clinical Infectious Diseases 47 (2008): 503-509.
14. Liu J., et al. “Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARSCoV- 2 infected patients”. EBioMedicine 55 (2020):
15. Waizel-Haiat S., et al. “A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19”. Cureus2 (2021): e13163.
16. Sweeny JM., et al. “Evidence for secondary thrombotic microangiopathy in COVID-19”. MedRxiv preprint (2021).
17. Vandroux D., et al. “Mortality of critically ill patients with severe influenza starting four years after the 2009 pandemic”. Infectious Disease11-12 (2019): 831-837.
18. Scheckenbach K., et al. “Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis”. Auris Nasus Larynx 37 (2010): 322e328.
19. Singh VP., et al. “Sinonasal Mucormycosis: A to Z”. Indian Journal of Otolaryngology and Head and Neck Surgery 71 (2019): 1962-1971.
20. Shah K., et al. “Orbital Exenteration in Rhino-Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring System”. Indian Journal of Otolaryngology and Head and Neck Surgery2 (2019): 259-265.
21. Mekonnen ZK., et al. “Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome”. Ophthalmic Plastic and Reconstructive Surgery2 (2021).
22. E Bouza., et al. “Mucormycosis: an emerging disease?” Clinical Microbiology and Infection 12 (2006): 7-23.
23. DeShazo RD., et al. “Fungal sinusitis”. The New England Journal of Medicine 337 (1997): 254-259.
24. Millon L., et al. “Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)”. Clinical Microbiology and Infection22 (2016): 810.e1-810.e8.
25. Lone PA., et al. “Rhino-orbito-cerebral mucormycosis: Magnetic resonance imaging”. Indian Journal of Otology 21 (2015): 215-218.
26. Radner AB., et al. “Acute invasive rhinocerebral zygomycosis in an otherwise healthy patient: case report and review”. Clinical Infectious Diseases 20 (1995): 163-166.
27. Piromchai P and Thanaviratananich S. “Impact of treatment time on the survival of patients suffering from invasive fungal rhinosinusitis”. Clinical Medicine Insights: Ear, Nose and Throat 7 (2014): 31-34.
28. Walsh TJ., et al. “Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases”. Clinical Infectious Diseases 26 (1998): 1383-1396.
29. Riley TT., et al. “Breaking the mold: a review of mucormycosis and current pharmacological treatment options”. Annals of Pharmacotherapy9 (2016): 747-757.
30. Lewis RE., et al. “Activity of deferasirox in Mucorales: influences of species and exogenous iron”. Antimicrobial Agents and Chemotherapy 55 (2011): 411-413.
31. Ibrahim AS., et al. “The iron chelator deferasirox protects mice from mucormycosis through iron starvation”. Journal of Clinical Investigation 117 (2007): 2649-2657. 

Citation

Citation: Vikasdeep Gupta and Vandana Sharma. “Covid Associated Mucormycosis: What do we Know Till Now?".Acta Scientific Otolaryngology 4.4 (2022): 70-74.

Copyright

Copyright: © 2022 Vikasdeep Gupta and Vandana Sharma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.